# Acute L-Leucine Supplementation and Sprint Exercise Elicit Distinct Appetite and Inflammatory Responses in Persons with Overweight: A Randomized, Counterbalanced, and Crossover Design Study

**Authors:** Elias de França, Ronaldo Vagner Thomatieli-Santos, Rita de Cássia Aquino, Mykaelen Malaquias Cavalcante, Beatriz Rugila Salvalágio, Peter Hofmann, Raul A. Martins, Liliana C. Baptista, Fabio Santos Lira, Erico das Chagas Caperuto

PMC · DOI: 10.3390/nu18040614 · 2026-02-13

## TL;DR

This study finds that sprint exercise and L-leucine supplementation can reduce appetite and food intake in overweight individuals, with distinct effects on appetite-related hormones and inflammation.

## Contribution

The study reveals distinct appetite and inflammatory responses to acute L-leucine supplementation and sprint exercise in overweight individuals.

## Key findings

- Sprint exercise and L-leucine reduced subjective appetite compared to placebo.
- Exercise with placebo improved satiety more than other conditions.
- Inflammatory markers like IL-6 increased with L-leucine but decreased with exercise alone.

## Abstract

Objectives: Our objective was to evaluate the acute effect of L-leucine supplementation and high-intensity sprint exercise on appetite-controlling neuropeptides and their association with the subjective perception of appetite (SPA), satiety (SPS), food intake, and inflammatory response in overweight participants. Methods: In a double-masked, randomized, counterbalanced, and crossover design, 12 sedentary overweight adult men performed four experiments: (1) exercise and L-leucine (EX-Leu), (2) exercise and placebo (EX-PLA), (3) L-leucine without exercise (SED-Leu), and (4) placebo without exercise (SED-PLA). The supplementation consisted of three daily doses of 70 mg/kg body weight of L-leucine or placebo (on the day of exercise and one day after). During the experiments, we recorded the food intake, SPA, and SPS, and evaluated the neuropeptides (GLP-1, PYY, CCK, and ghrelin) and cytokines (IL1-beta, IL-6, IL-10, and TNF-α) in peripheral blood. The acute exercise trial consisted of four sets of 30 sec cycle ergometer sprint exercises. Results: EX-Leu, EX-PLA, and SED-Leu decreased SPA, compared to SED-PLA; only EX-PLA improved SPS; EX-PLA and EX-Leu reduced food intake. GLP-1 decreased in the EX-PLA trial compared to SED-Leu. IL-6 and IL1-β levels increased in the EX-Leu trial compared to SED-PLA. An anti-inflammatory profile was identified in the EX-PLA trial compared to the other trials. Both neuropeptides (increased) and cytokines (a pro-inflammatory profile) were associated with changes in SPA, SPS, and food intake. Conclusions: The acute inflammatory balance induced by EX-Leu seems to improve appetite control. Sprint exercise had a consistent acute anorexic effect, while isolated L-leucine decreased SPA, but their impact on SPS and food intake is not clear (FAPESP grants: 2020/09936-2 and 2021/03601-1).

## Linked entities

- **Proteins:** GCG (glucagon), PYY (peptide YY), CCK (cholecystokinin), GHRL (ghrelin and obestatin prepropeptide), IL1B (interleukin 1 beta), IL6 (interleukin 6), IL10 (interleukin 10), TNF (tumor necrosis factor)
- **Chemicals:** L-leucine (PubChem CID 857)

## Full-text entities

- **Genes:** LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, TBX4 (T-box transcription factor 4) [NCBI Gene 9496] {aka ICPPS, PAPPAS, SPS}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, SFTPA1 (surfactant protein A1) [NCBI Gene 653509] {aka COLEC4, ILD1, PSP-A, PSPA, SFTP1, SFTPA1B}, SEPHS1 (selenophosphate synthetase 1) [NCBI Gene 22929] {aka SELD, SPS, SPS1, VERBRAS2}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CCK (cholecystokinin) [NCBI Gene 885], GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PYY (peptide YY) [NCBI Gene 5697] {aka PYY-I, PYY1}
- **Diseases:** vomiting (MESH:D014839), hyperphagia (MESH:D006963), appetite (MESH:D001068), Overweight (MESH:D050177), type 2 diabetes (MESH:D003924), inflammatory cytokines (MESH:D000080424), obese (MESH:D009765), nausea (MESH:D009325), reduction (MESH:D015431), insulin resistance (MESH:D007333), cardiovascular, muscular, joint, or bone problems (MESH:D002318), cancer (MESH:D009369), blood pressure oscillation (MESH:D006973), Inflammatory (MESH:D007249), injury to (MESH:D014947), bitter taste (MESH:D013651)
- **Chemicals:** Isomaltulose (MESH:C008189), BCAA (MESH:D000597), alcohol (MESH:D000438), LPS (MESH:D008070), PLA (MESH:C033616), water (MESH:D014867), L-Leucine (MESH:D007930), carbon dioxide (MESH:D002245), carb (MESH:D002241), PMSF (MESH:D010664), EDTA (MESH:D004492), oxygen (MESH:D010100), caffeine (MESH:D002110), aluminum (MESH:D000535), fat (MESH:D005223), EX (-)
- **Species:** Citrus x limon (lemon, species) [taxon 2708], Equus caballus (domestic horse, species) [taxon 9796], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Escherichia coli (E. coli, species) [taxon 562]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943545/full.md

---
Source: https://tomesphere.com/paper/PMC12943545